We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack. The Thousand Oaks, California-based drugmaker didn ...

Shares of Amgen Inc. AMGN advanced 1.24% to $297.93 Thursday, on what proved to be an all-around dismal trading session for ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Readers hoping to buy Amgen Inc. (NASDAQ:AMGN ... one business day before the record date which is the date on which a company determines the shareholders eligible to receive a dividend.

Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Amgen in a research note issued to ...

Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

Investment analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report released on Wednesday, February 5th. William Blair analyst M. Phipps now anticipates that ...